NP-1250, an ABCG2 inhibitor, induces apoptotic cell death in mitoxantrone-resistant breast carcinoma MCF7 cells via a caspase-independent pathway

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1492-1500

  Ito, Masumi ^a,b   Kajino, Kazunori ^a   Abe, Masaaki ^a   Fujimura, Tsutomu ^c   Mineki, Reiko ^c   Ikegami, Takako ^c   Ishikawa, Toshihisa ^d   Hino, Okio ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Nippon Chemiphar Co Ltd   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

ABCG2; Apoptosis; Breast cancer; Caspase independent cell death; Mitoxantrone resistance

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN INHIBITOR; CASPASE; MITOXANTRONE; NP 1250; PROTEIN INHIBITOR; STAUROSPORINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOMA CELL; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CASPASES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MITOXANTRONE; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 84874753674     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2249     Document Type: Article

References (20)

1. Scheffer GL, Maliepaard M, Pijnenborg AC, et al: Breast cancer resistance protein is localized at the plasma membrane in mito¬xantrone-and topotecan-resistant cell lines. Cancer Res 60: 2589 2593, 2000.
2. Kuo MT: Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol 608: 23-30, 2007.
3. Guo X, Ma N, Wang J, Song J, Bu X, Cheng Y, et al: Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 8: 375, 2008.
4. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, et al: RPN2 gene confers docetaxel resis¬tance in breast cancer. Nat Med 14: 939-948, 2008.
5. Katoh SY, Ueno M and Takakura N: Involvement of MDR1 function in proliferation of tumour cells. J Biochem 143: 517 524, 2008.
6. Chen Z, Liu F, Ren Q, Zhao Q, Ren H, Lu S, et al: Suppression of ABCG2 inhibits cancer cell proliferation. Int J Cancer 126: 841 851, 2010.
7. Nakagawa M, Schneider E, Dixon KH, Horton J, Kelley K, Morrow C and Cowan KH: Reduced intracellular drug accumulation in the absence of P-Glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 52: 6175-6181, 1992.
8. Wakabayashi K, Nakagawa H, Adachi T, Kii I, Kobatake E, Kudo A and Ishikawa T: Identification of cysteine residues criti¬cally involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. J Exp Ther Oncol 5: 205 222, 2006.
9. Saito H, Hirano H, Nakagawa H, Fukami T, Oosumi K, Murakami K, et al: A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interac-tions. J Pharmacol Exp Ther 317: 1114-1124, 2006.
10. Wang T, Kajino K, Abe M, Tan K, Maruo M, Sun G, et al: Suppression of cell death by the secretory form of N-terminal ERC/mesothelin. Int J Mol Med 26: 185-191, 2010.
11. Fujimura T, Shinohara Y, Tissot B, Pang PC, Kurogochi M, Saito S, et al: Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease of normal subjects. Int J Cancer 122: 39-49, 2008.
12. Janicke RU, Sprengart ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360, 1998.
13. Wilkinson B and Gilbert HF: Protein disulfide isomerase. Biochim Biophys Acta 1699: 35-44, 2004.
14. Keenan J, Murphy L, Henry M, Meleady P and Clynes M: Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line. Proteomics 9: 1556-1566, 2009.
15. Liu Y, Liu H, Han B and Zhang JT: Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 66: 3248 3255, 2006.
16. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P and Katzenellenbogen BS: An estrogen receptor-selec¬tive coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci USA 96: 6947-6952, 1999.
17. Zubovych I, Doundoulakis T, Harran PG and Roth MG: A missense mutation in Caenorhabditis elegans prohibitin 2 confers an atypical multidrug resistance. Proc Natl Acad Sci USA 103: 15523 15528, 2006.
18. Shau H and Kim A: Identification of natural killer enhancing factor as a major antioxidant in human red blood cells. Biochem Biophys Res Commun 199: 83-88, 1994.
19. Kowaltowski AJ, Netto LE and Vercesi AE: The thiol-specific antioxidant enzyme prevents mitochondrial permeability transi-tion evidence for the participation of reactive oxygen species in this mechanism. J Biol Chem 273: 12766-12769, 1998.
20. Chung YM, Yoo YD, Park JK, Kim YT and Kim HJ: Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res 21: 1129-1133, 2001.